Location History:
- Asturias, ES (2015)
- Austrias, ES (2018)
Company Filing History:
Years Active: 2015-2018
Title: Innovations in Antimicrobial Agents by Pilar Garcia Suarez
Introduction
Pilar Garcia Suarez is an accomplished inventor based in Austrias, Spain. He has made significant contributions to the field of antimicrobial agents, particularly through his innovative research on peptidoglycan hydrolases. With a total of two patents to his name, his work has the potential to revolutionize the treatment of bacterial infections.
Latest Patents
Pilar's latest patents focus on virion-associated peptidoglycan hydrolases, which have shown promise as antimicrobial agents due to their ability to lyse Gram-positive bacteria upon contact. One of his notable inventions involves fusion proteins, HydH5SH3b and HydH5Lyso, which combine the full-length peptidoglycan hydrolase HydH5 from the bacteriophage vB_SauS-phi-IPLA88 with the SH3b cell wall-binding domain from lysostaphin. These proteins exhibited high lytic activity against live cells, including methicillin-resistant Staphylococcus aureus (MRSA). Another patent highlights the efficacy of HydH5 and its derivatives in lysing both bovine and human MRSA strains, demonstrating their potential for antimicrobial synergy when used in combination with the endolysin LysH5.
Career Highlights
Pilar Garcia Suarez is currently associated with the United States of America, as represented by the Secretary of Agriculture. His research has garnered attention for its innovative approach to combating bacterial infections, particularly those caused by resistant strains.
Collaborations
Pilar has collaborated with notable colleagues, including David M Donovan and Lorena Rodriguez Rubio, who have contributed to his research endeavors.
Conclusion
Pilar Garcia Suarez's work in developing antimicrobial agents through innovative peptidoglycan hydrolases represents a significant advancement in the fight against bacterial infections. His contributions are paving the way for more effective treatments in the future.